Calendar

Join us for an informative and engaging webinar where we will explore the changing landscape of digital communication between biopharma companies and healthcare decision makers (HCDMs). In this live session, we will delve into 3 key topics that are crucial for effective management in the digital era:

• The latest research on how HCDMs are utilizing digital resources and gain valuable insights into their preferences.
• How manufacturers are adapting to meet the evolving needs of HCDMs in a post-pandemic peak era.
• The transformative power of artificial intelligence in digital communications and the implications for dynamics between biopharma companies and HCDMs.

Did you know that pharmacists in managed health care organizations are responsible for the delivery of health care and prescription drug benefits to over 300 million Americans? Are you a student pharmacist, new to managed care pharmacy, or considering a career transition and want to better understand managed care pharmacy and its many career opportunities? Join members of the AMCP Membership Committee as we answer the question, "what is managed care pharmacy and what roles do pharmacists play in it?"

Goal directed therapy is foundational to rational pharmacotherapy as well as the development of treatment guidelines. Importantly, treatment goals are not static and must evolve as a function of an evolving understanding of a given disease and the availability of more effective treatments. Innovations in rheumatology are enabling more patients to achieve higher levels of response and continue to facilitate the research necessary to define and refine treatment goals over time. 

The objective of this webinar is to review the evolution of goal directed therapy in rheumatology and discuss the clinical and health-economic value of goal-directed therapy and how payers can support goal-directed therapy.

Learning Objectives

• Review current treatment goals in rheumatology, progress toward goal attainment, and current practice patterns in rheumatology.
• Describe the clinical and health-economic value of achieving treatment goals in rheumatology and how payers can support goal directed therapy to improve the value of costly TIMs therapies.

Many patients with Major Depressive Disorder (MDD) require augmentation of their antidepressant with an additional therapy, and augmentation with an atypical antipsychotic is a guideline-recommended option for appropriate MDD patients. This session will focus on the burden of MDD and the impact of an atypical antipsychotic approved for the adjunctive treatment of MDD.

• Recognize the humanistic and economic burden of MDD.
• Describe where atypical antipsychotics fit within the treatment paradigm.
• Review the efficacy and safety data of an atypical antipsychotic as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.

Patients with lupus can present with diverse signs and symptoms affecting multiple organ systems. Lupus is a disease of progressive, and often irreversible, organ damage, which can lead to increased healthcare resource utilization and all-cause healthcare costs. Factors such as long-term use of corticosteroids and high disease activity may increase the risk of organ damage. Lupus nephritis, a serious manifestation of lupus, may lead to significant chronic kidney disease. Delays in treatment are another factor that may result in long-term organ damage. Modifying the natural course of the disease and minimizing corticosteroid exposure has been shown to prevent organ damage.

By the end of the program, you will be able to:

• Review the pathophysiology and clinical manifestations of lupus
• Discuss the clinical and economic impact of organ damage in the disease course of lupus
• Understand key components of disease modification and review strategies to prevent organ damage in lupus

This webinar is intended for US Formulary Decision Makers only.

This webinar explores the evolution of the treatment landscape, goals of treatment, and managed care considerations in Chronic Lymphocytic Leukemia (CLL) and provides an update on the new clinical data and real-world evidence for a targeted therapy in the treatment of patients living with CLL.   

Learning Objectives

• Review the CLL disease state, evolving treatment goals, and remaining unmet needs
• Outline patient, disease, clinical and health-economic considerations for managed care in the treatment of CLL
• Describe the efficacy and safety of a targeted therapy, fixed treatment duration regimen in CLL
• Provide an overview of the real-world experience of a fixed treatment duration regimen in CLL

A Payer-Only Webinar sponsored by Otsuka America Pharmaceutical, Inc.

This sponsored webinar will provide an overview of the Digital Therapeutics (DTx) Coverage Expectations Surveys conducted by Otsuka America Pharmaceutical, Inc. These surveys share insights and educate the audience on payers' experiences, perceptions, and readiness for coverage of DTx.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

Endometriosis is a chronic, estrogen-dependent inflammatory disease characterized by chronic pelvic pain and infertility, that can have a significant impact in some patients on quality of life, function, and healthcare costs.  The total annual societal burden of endometriosis in the United States is estimated to be $69.4 billion, of which indirect and direct costs comprise 66% and 34%, respectively.  Endometriosis disease peaks at the most productive working- years and contributes to a loss of 1.1 hours per week of employment productivity because of absenteeism and an average loss of 5.3 hours per week due to presenteeism.  Therefore, early diagnosis and treatment is crucial for the best outcome and relief of symptoms. 

The objective of this webinar is to understand the burden of endometriosis and its impact on quality of life, which is essential to developing an individualized treatment approach to address each patient’s unique needs.  Additionally, we will review the current treatment landscape as well as data from a clinical trial program for endometriosis associated pain.

The objective for this webinar, conducted by Abbvie Medical Affairs, is to review the migraine disease state and discuss the treatment landscape, with a focus on an acute treatment option.

Approximately 5%-10% of all asthma patients in the US have severe asthma. Patients with severe asthma who are uncontrolled are at risk for oral corticosteroid dependence, exacerbations, and progressive loss of lung function. Clinical remission has been proposed as a new target for patients with severe asthma with the goal of slowing or stopping disease progression. The concept of clinical remission takes a more holistic view of the disease in that it includes achieving a combination of parameters and not a single endpoint such as symptom relief. Similar to the evolution observed with other inflammatory disease states, such as rheumatoid arthritis, availability of new therapies allows for the consideration as to whether clinical remission is an achievable treatment target in severe asthma. This program will provide disease education for population-based decision makers to inform on the concept of clinical remission and next steps in elevating clinical remission as a goal for asthma.

Objectives:

• Describe the evolution of clinical remission as a target in other chronic inflammatory diseases  
• Share perspective of the value of achieving clinical remission, for patients with severe asthma, including improvements in daily life and long-term outcomes
• Define components of clinical remission for severe asthma and trajectory of this goal

Crohn’s Disease is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability.  The American Gastroenterological Association treatment guidelines for moderate to severe Crohn’s Disease have been updated and new long-term goals for the management of the disease have been established.

Clinical advancement of the treatment of moderate to severe Crohn’s Disease have included therapeutic options with diverse mechanisms of action.  Head-to-head trials play an important role in advancing the science for HCPs and HCDMs responsible for the treatment of patients with Crohn’s Disease.  The SEQUENCE trial design consisted of randomizing patients with moderate to severe CD who have failed TNF therapy to two treatments arms, an IL-23 inhibitor and an IL-12/23 inhibitor with a goal of assessing both clinical and endoscopic endpoints.